[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371411-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371411-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","development-of-relb-targeting-small-molecule-inhibitors-of-non-canonical-nf-kb-signaling-with-antitumor-efficacy","Development of RelB-targeting small-molecule inhibitors of non-canonical NF-kB signaling with antitumor efﬁcacy","","Dysfunction of the non-canonical NF-kB signaling pathway is linked to multiple cancers and autoimmune diseases, yet targeted inhibitors have remained limited. Using structure-based cell-based screening, the study identifies a potent, selective small molecule that targets RelB and selectively inhibits non-canonical NF-kB signaling without affecting the canonical pathway. The compound directly binds RelB, disrupts its DNA binding, and represses RelB-driven transcriptional activity, producing strong antitumor effects in vitro and in vivo.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/development-of-relb-targeting-small-molecule-inhibitors-of-non-canonical-nf-kb-signaling-with-antitumor-efficacy/371411/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/development-of-relb-targeting-small-molecule-inhibitors-of-non-canonical-nf-kb-signaling-with-antitumor-efficacy/371411.png","ImageObject",300,407,{"name":42,"@type":43},"Margaret","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address regarding NF-kB signaling?","Question",{"text":63,"@type":64},"It addresses that non-canonical NF-kB pathway dysfunction contributes to cancers and autoimmune diseases, while specific inhibitors for this pathway are still needed.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the RelB-targeting inhibitor identified?",{"text":68,"@type":64},"The inhibitor was obtained through structure-based cell-based screening to find a potent and specific small molecule targeting RelB.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the proposed mechanism of action of the inhibitor?",{"text":72,"@type":64},"The inhibitor directly interacts with the RelB protein, disrupts RelB binding to target DNA, and represses RelB transactivity on target genes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371411,1790218683,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Original Article  \nDevelopment of RelB-targeting small-molecule inhibitors of non-canonical NF-kB  \nsignaling with antitumor efﬁcacy  \nCuifeng Li, 1,2,3,9 Shuqi Wei, 1,9 Donglin Sun, 1,4,9 Zhuo Yang,5,9 Qi Wang, 1,2,9 Han Lin, 1 Haohao Zhang, 1,2 Yiming Hu, 1,2 Dandan Liu, 1,2 Deji Ye, 1,2 Yu Tao,2 Zhanjie Liu,2 Zhijian Xu,5 Bo Li,5 Lingling Li,2 Jie Zhang,2 Xi Chen, 1,2 Ningxia Xie, 1,2 Yufang Shi,2 Sanhong Liu,2,6 Yongzhong Liu,7 Yuhang Jiang, 1,2,8 Weiliang Zhu,5 and Xiaoren Zhang1,2  \n1The Second Afﬁliated Hospital, The Sixth Afﬁliated Hospital, Afﬁliated Cancer Hospital and Institute, GMU-GIBH Joint School of Life Sciences of Guangzhou Medical University, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangdong Provincial Key Laboratory of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, Guangzhou 510000, China; 2CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China; 3School of Life Sciences, Tsinghua University, Beijing 100084, China; 4Department of Urology, Shenzhen Hospital, Southern Medical University, Shenzhen 518000, China; 5CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 201203, China; 6Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; 7State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200032, China; 8Department of Orthopedics, The Eighth Afﬁliated Hospital of Sun Yat-sen University, Shenzhen 518033, China  \nDysfunction of the non-canonical nuclear factor kB (NF-kB) signaling pathway has been causally associated with numbers of cancers and autoimmune diseases. However, speciﬁc inhibitors for this signaling pathway remain to be developed. Here, we showed that structure-based cell-based screening yielded a potent and speciﬁc small molecule targeting RelB to inhibit thenon-canonical NF-kB signaling pathway, while it had no inhibitory effect on the canonical NF-kB signaling pathway. Mechanistically, the inhibitor directly interacted with RelB protein and disrupted RelB binding to its target DNA, thus repressing RelB transactivity on target genes. Through blocking oncogenic activity of the non-canonical NF-kB signaling pathway in colorectal cancer or B lymphoma, the inhibitor efﬁciently exerted a potent antitumor effect in vitro and in vivo. Thus, our study provided a new RelB-targeting inhibitor that inhibited the non-canonical NF-kB signaling pathway and facilitated precise therapeutic applications in cancers and possibly other diseases.  \nINTRODUCTION  \nThe transcription factor nuclear factor kB (NF-kB) family, including RelA (p65), RelB, c-Rel, NF-kB1 (p50/p105), and NF-kB2 (p52/ p100), regulates expression of numerous genes involved in immune response, inﬂammation, cell survival, and cancers.1–3 A Rel homology domain conserved in all NF-kB members is responsible for their dimerization, nuclear translocation, and DNA binding.4 NF-kB activation occurs via two major signaling pathways: the canonical and thenon-canonical NF-kB signaling pathways. The canonical pathway mediates the activation of NF-kB1 (p50), RelA, and c-Rel, whereas  \nthe non-canonical NF-kB pathway selectively activates p100-sequestered NF-kB members, predominantly NF-kB2 (p52) and RelB. The canonical NF-kB pathway responds to stimuli from diverse immune receptors and leads to rapid but transient nuclear translocation of the prototypical NF-kB heterodimer RelA/p50 .5–7 The non-canonical NF-kB pathway relies on phosphorylation-induced p100 processing, whi","cbCaiv2o1DBcUZhY","https://ap.wps.com/l/cbCaiv2o1DBcUZhY","pdf",7177121,16,"English","# Introduction\n## Non-canonical vs canonical NF-kB signaling pathways","[{\"question\":\"What problem does the study address regarding NF-kB signaling?\",\"answer\":\"It addresses that non-canonical NF-kB pathway dysfunction contributes to cancers and autoimmune diseases, while specific inhibitors for this pathway are still needed.\"},{\"question\":\"How was the RelB-targeting inhibitor identified?\",\"answer\":\"The inhibitor was obtained through structure-based cell-based screening to find a potent and specific small molecule targeting RelB.\"},{\"question\":\"What is the proposed mechanism of action of the inhibitor?\",\"answer\":\"The inhibitor directly interacts with the RelB protein, disrupts RelB binding to target DNA, and represses RelB transactivity on target genes.\"}]","Development of RelB-targeting small-molecule inhibitors of non-canonical NF-kB signaling with antitumor efﬁcacy | PDF",1790192007,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/792f0243c93cc35a16e5dc318cc9bc67.webp",983,1276,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/846aef2ecee1f2bba4329c27d5e75c74.webp",982,1275,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cac087084fb98631ac7b85f96a60e91.webp",981,1273,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01456ba81a9ee61eab1635b6c79ba697.webp",980,1272]